In the present study, we compared the impact of established prognostic factors and parameters reflecting the multidrug resistance (MDR) phenotype of tumor cells (drug responsiveness, MDR1 mRNA/P-gp expression) on the therapy response and, as a result, the prognosis for AML patients. This evidence concerns the gene PGP and acute myeloid leukemia.